WallStreetZenWallStreetZen

NASDAQ: PALI
Palisade Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PALI

Based on 6 analysts offering 12 month price targets for Palisade Bio Inc

Min Forecast
$5.00+160.42%
Avg Forecast
$10.50+446.88%
Max Forecast
$25.00+1,202.08%

Should I buy or sell PALI stock?

Based on 6 analysts offering ratings for Palisade Bio Inc.

Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PALI's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates PALI as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their PALI stock forecasts and price targets.

PALI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-09
lockedlocked$00.00+00.00%2026-03-26
lockedlocked$00.00+00.00%2026-02-25
lockedlocked$00.00+00.00%2026-01-09
lockedlocked$00.00+00.00%2025-12-30
Piper Sandler
Top 5%
96
Strong BuyInitiates Coverage On$25.00+1,202.08%2025-12-29

1 of 1

Forecast return on equity

Is PALI forecast to generate an efficient return?

Company
-52.13%
Industry
75.1%
Market
170.33%
PALI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PALI forecast to generate an efficient return on assets?

Company
-49.8%
Industry
28.98%
PALI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PALI earnings per share forecast

What is PALI's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$0.21-395.57%
Avg 2 year Forecast
-$0.24-447.57%
Avg 3 year Forecast
-$0.30-533.57%

PALI revenue forecast

What is PALI's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

PALI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PALI$1.92$10.50+446.88%Strong Buy
IMRX$5.18$15.50+199.23%Strong Buy
LCTX$1.33$6.25+369.92%Strong Buy
CMPX$1.87$15.50+728.88%Strong Buy
ARMP$9.00$15.00+66.67%Strong Buy
View Top Biotech Stocks

Palisade Bio Stock Forecast FAQ

Is Palisade Bio Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: PALI) stock is to Strong Buy PALI stock.

Out of 6 analysts, 4 (66.67%) are recommending PALI as a Strong Buy, 2 (33.33%) are recommending PALI as a Buy, 0 (0%) are recommending PALI as a Hold, 0 (0%) are recommending PALI as a Sell, and 0 (0%) are recommending PALI as a Strong Sell.

If you're new to stock investing, here's how to buy Palisade Bio stock.

What is PALI's earnings growth forecast for 2026-2028?

(NASDAQ: PALI) Palisade Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.27%.

Palisade Bio's earnings in 2026 is -$24,151,000.On average, 9 Wall Street analysts forecast PALI's earnings for 2026 to be -$35,913,634, with the lowest PALI earnings forecast at -$49,331,342, and the highest PALI earnings forecast at -$12,758,106. On average, 9 Wall Street analysts forecast PALI's earnings for 2027 to be -$42,231,934, with the lowest PALI earnings forecast at -$59,537,827, and the highest PALI earnings forecast at -$21,871,038.

In 2028, PALI is forecast to generate -$52,681,430 in earnings, with the lowest earnings forecast at -$52,733,504 and the highest earnings forecast at -$51,032,423.

What is PALI's revenue growth forecast for 2026-2028?

(NASDAQ: PALI) Palisade Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.

Palisade Bio's revenue in 2026 is $0.On average, 7 Wall Street analysts forecast PALI's revenue for 2026 to be $0, with the lowest PALI revenue forecast at $0, and the highest PALI revenue forecast at $0. On average, 7 Wall Street analysts forecast PALI's revenue for 2027 to be $0, with the lowest PALI revenue forecast at $0, and the highest PALI revenue forecast at $0.

In 2028, PALI is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is PALI's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: PALI) forecast ROA is -49.8%, which is lower than the forecast US Biotechnology industry average of 28.98%.

What is PALI's Price Target?

According to 6 Wall Street analysts that have issued a 1 year PALI price target, the average PALI price target is $10.50, with the highest PALI stock price forecast at $25.00 and the lowest PALI stock price forecast at $5.00.

On average, Wall Street analysts predict that Palisade Bio's share price could reach $10.50 by Apr 9, 2027. The average Palisade Bio stock price prediction forecasts a potential upside of 446.88% from the current PALI share price of $1.92.

What is PALI's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: PALI) Palisade Bio's current Earnings Per Share (EPS) is $0.07. On average, analysts forecast that PALI's EPS will be -$0.21 for 2026, with the lowest EPS forecast at -$0.28, and the highest EPS forecast at -$0.07. On average, analysts forecast that PALI's EPS will be -$0.24 for 2027, with the lowest EPS forecast at -$0.34, and the highest EPS forecast at -$0.13. In 2028, PALI's EPS is forecast to hit -$0.30 (min: -$0.30, max: -$0.29).

What is PALI's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: PALI) forecast ROE is -52.13%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.